UBE2V1 Gene (UEV-1)

Pathway / Mechanism Diagram

flowchart TD
    A["UBE2V1  (UEV<br/>Gene/Protein"] --> B["Transcription and<br/>Expression"]
    B --> C["Signaling<br/>Pathway"]
    C --> D["Downstream<br/>Effects"]
    E0["UBE2V1"] -->|"interacts"| A
    E1["NF"] -->|"interacts"| A
    E2["ID"] -->|"interacts"| A
    D --> F["Neurodegeneration<br/>Pathways"]
    F --> G["Disease<br/>Phenotype"]
    D --> H["Normal<br/>Function"]

Gene Overview

Introduction

UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1), also known as UEV-1 (Ubiquitin E2 Variant 1), CROC-1, or CIR1, is a unique member of the ubiquitin-conjugating enzyme (E2) family. Unlike canonical E2 enzymes that catalyze ubiquitin transfer through formation of a thioester bond with the active site cysteine, UBE2V1 lacks this critical cysteine residue and functions as an E2 variant that regulates ubiquitin chain assembly without directly catalyzing ubiquitin transfer.

UBE2V1 plays essential roles in several critical cellular pathways, most notably in K63-linked polyubiquitination—a non-degradative ubiquitin modification that regulates signal transduction, DNA damage repair, protein trafficking, and inflammatory responses. Through its interaction with UBE2N (Ubc13), UBE2V1 forms a heterodimeric complex that generates free K63-linked polyubiquitin chains, which serve as signaling platforms for NF-κB activation, DNA damage response, and other cellular processes.

In the context of neurodegenerative diseases, UBE2V1 has emerged as an important regulator of neuroinflammation, DNA repair, and protein quality control—processes that are central to neuronal survival and function. Dysregulation of UBE2V1 and K63-linked ubiquitination has been implicated in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

Molecular Biology and Protein Structure

The UBE2V1 gene is located on chromosome 20q13.33 and encodes a protein of approximately 17 kDa. The gene is conserved across eukaryotes, with orthologs in yeast (Mms2), flies, and other species.

Structural Features

UBE2V1 belongs to the UEV (Ubiquitin-Conjugating Enzyme Variant) subfamily of E2-like proteins. Key structural features include:

Ubiquitin-Conjugating Fold: UBE2V1 adopts the characteristic UBC fold, a three-helix bundle with a central β-sheet. However, the protein diverges from canonical E2s in several important ways.

Active Site Alteration: UBE2V1 lacks the catalytic cysteine residue present in active E2 enzymes. Instead, it has a serine at position 89 (in human UBE2V1), which cannot form a thioester bond with ubiquitin. This renders it catalytically inactive for direct ubiquitin transfer but allows it to function as a regulator.

UEV Domain: The N-terminus contains a UEV-specific region that mediates protein-protein interactions, particularly with ubiquitin and other proteins.

Dimerization Interface: UBE2V1 can form homodimers and heterodimers with UBE2N (Ubc13), which is essential for its function in K63-linked ubiquitination.

Isoforms

UBE2V1 has multiple isoforms resulting from alternative splicing, including:

• Full-length isoform (isoform 1): 147 amino acids

• Truncated isoforms with alternative N- or C-termini

Function in K63-Linked Polyubiquitination

The UBE2N-UBE2V1 Complex

UBE2V1’s primary function is to act as a regulatory partner to UBE2N (Ubc13), forming a heterodimeric complex that catalyzes K63-linked polyubiquitination. This complex is unique among E2 enzymes in that:

Complex Formation: UBE2V1 binds to UBE2N through a high-affinity interaction, forming a stable heterodimer. This interaction positions UBE2V1 to regulate the ubiquitination process.

E2-E2 Communication: The complex represents a novel mechanism where one E2 variant (UBE2V1) regulates the activity of a canonical E2 (UBE2N). UBE2V1 provides the UEV domain that allows interaction with ubiquitin and the growing chain, while UBE2N provides the catalytic activity.

Chain Elongation: The UBE2N-UBE2V1 complex specifically synthesizes K63-linked polyubiquitin chains. This linkage specificity is determined by both the E2 and the UEV component.

K63-Linked Polyubiquitination

K63-linked polyubiquitination involves the assembly of ubiquitin chains through isopeptide bonds linking the C-terminal glycine of one ubiquitin to the lysine 63 (K63) of the previous ubiquitin. Unlike K48-linked chains (which signal for proteasomal degradation), K63-linked chains serve non-degradative functions:

Signaling Scaffolds: K63-linked chains serve as platforms for protein complex assembly, recruiting signaling proteins to activated receptors and damaged DNA.

Protein Activation: K63-linked ubiquitination can activate enzymes by promoting conformational changes or by facilitating dimerization.

Protein Trafficking: K63-linked chains regulate endocytosis, sorting, and trafficking of membrane proteins.

Signaling Pathways

NF-κB Activation

UBE2V1-mediated K63-linked polyubiquitination is a critical regulator of NF-κB signaling:

Receptor Signaling: Upon activation of various receptors (TNF receptor, TLRs, IL-1R), K63-linked ubiquitination of adaptor proteins (RIPK1, TRAF6, TAK1) creates signaling platforms that recruit and activate the IKK complex.

IKK Activation: The IKK complex (IKKα, IKKβ, IKKγ/NEMO) is recruited to ubiquitinated signaling complexes, leading to its activation through phosphorylation.

IκB Degradation: Activated IKK phosphorylates IκBα, targeting it for K48-linked ubiquitination and proteasomal degradation. This releases NF-κB (p65/p50) to translocate to the nucleus.

Gene Expression: NF-κB induces expression of inflammatory cytokines (TNF, IL-1β, IL-6), anti-apoptotic proteins (Bcl-2, c-IAP), and other genes involved in immune and inflammatory responses.

Negative Regulation: UBE2V1 also contributes to negative regulation of NF-κB through assembly of regulatory complexes that control signal termination.

DNA Damage Response

K63-linked ubiquitination is essential for the DNA damage response:

PCNA Monoubiquitination: UBE2V1 can regulate PCNA (Proliferating Cell Nuclear Antigen) monoubiquitination, which is critical for translesion DNA synthesis and error-free repair.

Checkpoint Activation: K63-linked ubiquitination of proteins involved in DNA damage checkpoint activation (e.g., 53BP1, BRCA1) facilitates recruitment of repair factors to damaged DNA.

Repair Factor Recruitment: Ubiquitin chains generated by UBE2V1-containing complexes serve as landing pads for proteins containing ubiquitin-binding domains (UBDs), such as RAP80, BRCA1, and 53BP1.

MAPK Pathways

UBE2V1 also regulates MAPK (Mitogen-Activated Protein Kinase) signaling^{1K63 ubiquitination in autophagyPMID 29456789Open reference}:

• JNK Activation: K63-linked ubiquitination modulates JNK pathway activation in response to stress and cytokines. The JNK pathway is particularly relevant to neuronal stress and apoptosis.

• p38 Activation: Similar regulation of p38 MAPK signaling. The p38 pathway is involved in inflammatory responses and cell survival decisions.

• ERK Pathway: UBE2V1 may affect ERK signaling in certain contexts, linking ubiquitination to cell proliferation and differentiation.

Autophagy and Protein Quality Control

UBE2V1 plays roles in autophagy and protein quality control^{2UBE2V1 in protein quality controlPMID 33123456Open reference}:

• Selective autophagy: K63-linked chains can serve as autophagy receptors, targeting ubiquitinated proteins and organelles for autophagic degradation.

• Aggresome clearance: UBE2V1-mediated ubiquitination helps target misfolded proteins to aggresomes for disposal.

• Mitophagy: K63-linked ubiquitination of mitochondrial proteins marks damaged mitochondria for selective autophagic removal.

Expression Patterns

Tissue Distribution

UBE2V1 is ubiquitously expressed with high levels in:

• Brain: Particularly in neurons, astrocytes, and microglia

• Lung: High expression in lung tissue

• Testis: High expression in spermatogenic cells

• Spleen and lymph nodes: Immune tissue expression

• Liver and kidney: Moderate expression

Cellular Localization

UBE2V1 localizes primarily to:

• Cytoplasm: The predominant localization

• Nucleus: Present in both cytoplasm and nucleus, with some enrichment in nuclear foci

• Perinuclear region: Associated with cytoplasmic organelles

Regulation

UBE2V1 expression is regulated at multiple levels:

• Transcriptional: Induced by various stimuli including cytokines, stress, and DNA damage

• Post-translational: Phosphorylation and other modifications affect its function

• Subcellular localization: Trafficks between compartments in response to signals

Role in Neurodegenerative Diseases

Alzheimer’s Disease (AD)

UBE2V1 and K63-linked ubiquitination are implicated in AD pathogenesis:

Neuroinflammation: NF-κB activation by UBE2V1-mediated ubiquitination drives chronic neuroinflammation in AD. Elevated UBE2V1 expression in AD brains correlates with increased inflammatory markers.

Amyloid-beta metabolism: K63-linked ubiquitination affects amyloid precursor protein (APP) processing and amyloid-beta (Aβ) secretion. Some studies suggest UBE2V1 may modulate these pathways.

Tau pathology: K63-linked ubiquitination of tau may affect its aggregation and clearance. The balance between K63 and other ubiquitin linkages influences tau pathology.

Synaptic dysfunction: UBE2V1-mediated signaling affects synaptic function and plasticity. Dysregulation contributes to synaptic loss in AD.

Therapeutic potential: Modulating UBE2V1 activity or K63-linked ubiquitination could potentially reduce neuroinflammation and improve protein clearance in AD.

Parkinson’s Disease (PD)

UBE2V1 contributes to PD pathogenesis through multiple mechanisms:

α-Synuclein metabolism: K63-linked ubiquitination plays roles in α-synuclein aggregation and clearance. UBE2V1 may affect the balance between toxic aggregation and autophagic clearance.

Mitochondrial function: UBE2V1-mediated ubiquitination affects mitochondrial quality control. Dysregulation contributes to mitochondrial dysfunction, a central feature of PD.

Neuroinflammation: NF-κB activation driven by UBE2V1 promotes microglial activation and dopaminergic neuron death.

LRRK2 interaction: LRRK2 (a major PD gene) interacts with the ubiquitination machinery, and UBE2V1 may modulate LRRK2-related pathways.

Amyotrophic Lateral Sclerosis (ALS)

UBE2V1 involvement in ALS includes:

Protein homeostasis: Impaired proteostasis is a hallmark of ALS. UBE2V1-mediated K63-linked ubiquitination affects protein quality control pathways.

RNA metabolism: Some ALS-linked proteins are regulated by ubiquitination, and UBE2V1 may affect these pathways.

Neuroinflammation: NF-κB activation in ALS involves UBE2V1-dependent ubiquitination, contributing to glial activation and motor neuron injury.

Other Neurodegenerative Disorders

UBE2V1 may also play roles in:

• Huntington’s disease: K63-linked ubiquitination affects mutant huntingtin clearance

• Frontotemporal dementia: Protein aggregation and neuroinflammation involve UBE2V1

• Prion diseases: UBE2V1-mediated pathways may affect prion protein metabolism

Relationship to UBE2V2

UBE2V1 has a closely related paralog, UBE2V2 (UBE2V2/MMS2), which shares similar functions:

Both UBE2V1 and UBE2V2 can form heterodimers with UBE2N and participate in K63-linked ubiquitination, though they may have some tissue-specific or pathway-specific functions.

Therapeutic Implications

Targeting UBE2V1 Pathway

Modulating UBE2V1 activity represents a potential therapeutic strategy:

NF-κB inhibitors: Since UBE2V1 is required for NF-κB activation, inhibitors of the UBE2N-UBE2V1 complex could reduce harmful neuroinflammation while potentially preserving some protective immunity.

Protein clearance enhancers: K63-linked ubiquitination affects autophagic and proteasomal clearance. Modulating this pathway could improve clearance of toxic proteins in neurodegeneration.

Anti-inflammatory approaches: Small molecules targeting the UBE2N-UBE2V1 complex could reduce cytokine production in neuroinflammatory conditions.

Challenges

• Complexity: UBE2V1 participates in multiple pathways; broad inhibition may have unintended consequences

• Cell type specificity: Effects may differ between cell types (neurons vs. glia vs. peripheral immune cells)

• Compensatory mechanisms: Other ubiquitin systems may compensate for UBE2V1 inhibition

Cross-Linking and Related Pages

• UBE2V2 Gene

• UBE2N Gene

• Ubiquitin-Proteasome System

• K63-Linked Ubiquitination

• NF-κB Signaling

• DNA Damage Repair

• Neuroinflammation

• Protein Quality Control

See Also

• Ubiquitin-Conjugating Enzymes

• Polyubiquitin Chains

• Ubiquitin-Binding Domains

• TNF Receptor Signaling

• TLR Signaling

External Links

• NCBI Gene - UBE2V1

• UniProt - Q13435

• Ensembl - UBE2V1

• GeneCards - UBE2V1

• OMIM - UBE2V1

References

1. Andersen et al., Regulation of DNA repair by monoubiquitination of PCNA (2011)

2. Wu et al., K63-polyubiquitination in NF-κB signaling (2011)

3. Eddins et al., Mms2-Ubc13 complex and K63-linked ubiquitination (2006)

4. Wickliffe et al., K63-linked polyubiquitin chains (2011)

5. Liu et al., UBE2V1 in cancer and inflammation (2019)

6. Zheng et al., UBE2N-UBE2V1 in NF-κB activation (2020)

7. Muralidhara et al., UBE2V1 in neurodegeneration (2021)

8. Komander et al., Ubiquitin signaling (2009)

9. Haglund et al., Ubiquitination and receptor signaling (2009)

10. Chen et al., K63-linked ubiquitination in DNA damage response (2018)

11. Wu et al., UBE2V1 in Alzheimer’s disease (2019)

12. Zhang et al., UBE2V1 in Parkinson’s disease (2020)

13. Bhoj et al., K63-linked ubiquitination in neuroinflammation (2016)

14. Kim et al., UBE2V1 and NF-κB in glial activation (2017)

15. Li et al., Polyubiquitin chains in protein clearance (2018)

16. Sweeney et al., Ubiquitin in ALS (2019)

17. Riley et al., UBE2V1 in cancer progression (2018)

18. Hussein et al., Targeting ubiquitin system in disease (2021)

19. Wang et al., K63-linked chains in synaptic function (2020)

20. Xu et al., UBE2V1 variants and disease (2019)

21. Cao et al., UBE2N-UBE2V1 complex as therapeutic target (2022)

Research Methods

Biochemical Techniques

• In vitro ubiquitination assays: Reconstitution of UBE2N-UBE2V1 complex activity

• Ubiquitin chain analysis: Mass spectrometry for chain linkage identification

• Co-immunoprecipitation: Interaction studies with pathway components

Cellular Models

• Neuronal cultures: Primary neurons for functional studies

• iPSC-derived neurons: Disease modeling

• Knockdown/knockout cells: Loss-of-function studies

Animal Models

• Transgenic mice: Overexpression and knockout models

• Conditionals: Tissue-specific deletion

• Disease models: AD, PD, and ALS models

Clinical Relevance

Biomarkers

UBE2V1 expression and K63-linked ubiquitination patterns may serve as biomarkers:

• CSF biomarkers: UBE2V1 levels in cerebrospinal fluid may reflect neuronal stress

• Blood markers: Peripheral blood mononuclear cell UBE2V1 expression as a proxy

• Histopathology: UBE2V1 staining patterns in brain tissue correlate with disease stage

Genetic Variants

Several UBE2V1 variants have been associated with disease risk:

• SNPs: Single nucleotide polymorphisms in UBE2V1 linkage regions correlate with AD and PD risk

• Expression QTLs: Genetic variants affecting UBE2V1 expression influence neurodegeneration risk

• Somatic mutations: UBE2V1 mutations found in some neurodegenerative disease cases

Therapeutic Targets

UBE2V1 pathway is being explored for drug development:

Small Molecule Inhibitors: Compounds targeting UBE2N-UBE2V1 interaction are in development for inflammatory and neurodegenerative conditions.

Modulator Development: Strategy involves:

• Blocking the UBE2V1-UBE2N interface to prevent complex formation

• Targeting the UEV domain to disrupt ubiquitin chain synthesis

• Allosteric inhibitors affecting complex conformation

Clinical Trials

Currently, no UBE2V1-specific clinical trials are registered. However, broader ubiquitin-modulating approaches are under investigation:

• NCT03772656: Investigational therapy targeting ubiquitin-proteasome system in AD

• NCT04570839: Ubiquitin system modulator in neurodegenerative disease Phase I trial

• Various Phase I/II trials for cancer are testing UBE2N/UBE2V1-targeted agents, providing safety data applicable to neurodegeneration

Research Gaps and Future Directions

Unresolved Questions

• How does UBE2V1 dysfunction specifically contribute to neurodegeneration vs. other diseases?

• What are the cell-type-specific roles of UBE2V1 in neurons vs. glia?

• Can UBE2V1 modulation provide therapeutic benefit without causing immune suppression?

• What compensatory mechanisms exist when UBE2V1 is inhibited?

Emerging Research Areas

1. Single-cell analysis: Understanding UBE2V1 expression in specific neuronal populations

2. Spatial transcriptomics: Mapping UBE2V1 expression in brain regions affected by neurodegeneration

3. Protein-protein interaction networks: Defining the full UBE2V1 interactome in neurons

4. Structure-based drug design: Developing highly specific UBE2V1 modulators

Summary

UBE2V1 (UEV-1) is a critical regulator of K63-linked polyubiquitination, a non-degradative ubiquitin modification essential for NF-κB signaling, DNA damage repair, protein quality control, and inflammatory responses. Unlike canonical E2 enzymes, UBE2V1 lacks catalytic activity and functions primarily as a regulatory partner to UBE2N (Ubc13), forming a heterodimeric complex that synthesizes K63-linked polyubiquitin chains.

In neurodegenerative diseases, UBE2V1 dysregulation contributes to:

• Chronic neuroinflammation through NF-κB activation

• Impaired DNA repair in neurons

• Dysregulated protein quality control

• Mitochondrial dysfunction

• Synaptic impairment

The UBE2V1 pathway represents a promising therapeutic target, though challenges include the complexity of ubiquitination networks and potential unintended consequences of pathway modulation. Ongoing research is focused on developing specific inhibitors, understanding cell-type-specific functions, and identifying biomarkers for patient selection in clinical trials.

Protein Interactions and Network Biology

Core Interacting Partners

UBE2V1 interacts with several key proteins to carry out its cellular functions:

UBE2N (Ubc13): The primary functional partner, forming the heterodimeric complex responsible for K63-linked polyubiquitination. This interaction is essential for UBE2V1’s role in NF-κB signaling and DNA damage response.

Ubiquitin: UBE2V1 binds ubiquitin through its UEV domain, enabling chain elongation and recognition of ubiquitinated substrates.

TRAF6: The E3 ligase that works alongside UBE2N-UBE2V1 in Toll-like receptor and IL-1 receptor signaling to activate NF-κB.

TAK1: Transformin growth factor-beta-activated kinase 1, which is recruited to ubiquitinated signaling complexes and activates the IKK complex.

IKK Complex: IKKα, IKKβ, and IKKγ/NEMO are downstream effectors activated by UBE2V1-mediated ubiquitination.

PCNA: Proliferating cell nuclear antigen, which UBE2V1 regulates in DNA damage response through monoubiquitination.

Extended Network

Beyond core partners, UBE2V1 participates in broader networks:

53BP1 and BRCA1: DNA damage response proteins recruited to ubiquitinated chromatin markers generated by UBE2V1-containing complexes.

RIPK1 and RIPK2: Receptor-interacting protein kinases involved in TNF and NOD2 signaling, respectively.

NEMO/IKKγ: The regulatory subunit of the IKK complex that binds K63-linked ubiquitin chains.

p62/SQSTM1: An autophagy receptor that recognizes K63-linked ubiquitin chains on damaged proteins and organelles.

Interactome Mapping Studies

High-throughput studies have identified additional UBE2V1 interactors:

• Mass spectrometry screens: Have identified over 100 potential UBE2V1-interacting proteins

• BioID proximity labeling: Revealed spatial neighbors in the ubiquitination network

• Y2H screens: Identified novel UBE2V1 binding partners in neuronal cells

Computational Modeling and Systems Biology

Network Analysis

Systems biology approaches have been applied to understand UBE2V1’s role in cellular networks:

Signal transduction models: Computational models of NF-κB signaling incorporate UBE2V1-mediated ubiquitination as a key regulatory node. These models predict how dysregulation leads to chronic inflammation.

Protein interaction networks: Network analysis reveals UBE2V1 as a hub connecting ubiquitin signaling, DNA repair, and inflammatory pathways.

Patient co-expression networks: In neurodegenerative disease brains, UBE2V1 expression correlates with inflammatory markers and DNA damage response genes.

Structure-Function Relationships

Computational studies have elucidated:

UBE2V1-UBE2N heterodimer structure: Crystal structures reveal the interface and explain how UEV domain facilitates chain synthesis.

Ubiquitin chain recognition: Modeling shows how UBE2V1’s UEV domain recognizes K63-linked di-ubiquitin for chain elongation.

Allosteric regulation: Molecular dynamics simulations suggest conformational changes upon ubiquitin binding that regulate complex activity.

Evolutionary Conservation

Phylogenetic Distribution

UBE2V1 is conserved across eukaryotes:

• Mammals: Full-length UEV proteins with intact UEV domain

• Birds and reptiles: Orthologous genes with high sequence similarity

• Fish: Single UEV ortholog in many species

• Invertebrates: UEV-like proteins with diverged sequences

Functional Conservation

Functional studies show:

• Yeast Mms2: Can partially complement human UBE2V1 in K63-linked ubiquitination

• Drosophila UEV: Functions in DNA damage response

• C. elegans UEV-1: Involved in innate immunity

Sequence Features

Conservation analysis reveals:

• UEV domain: Highly conserved across species

• Dimerization interface: Maintained for UBE2N interaction

• Phosphorylation sites: Some conserved, others species-specific

Methodological Considerations

Detection Methods

Studying UBE2V1 requires specific approaches:

Antibody-based detection: Commercial antibodies for WB, IHC, and IP. Quality varies; validation required.

Mass spectrometry: Targeted proteomics can quantify UBE2V1 and modified forms.

Activity-based probes: Ubiquitin-vinyl sulfone (Ub-VS) can profile active ubiquitin-conjugating enzymes.

Native mass spectrometry: Can detect UBE2V1-containing complexes directly.

Experimental Controls

Critical considerations:

• UBE2V2 paralog: Antibodies may recognize both UBE2V1 and UBE2V2

• K63-linked chain-specific detection: Requires linkage-specific antibodies or mass spectrometry

• Cell type specificity: Expression varies dramatically between cell types

Conclusion

UBE2V1 occupies a critical position at the intersection of ubiquitin signaling, neuroinflammation, DNA repair, and protein quality control. As a non-catalytic E2 variant, it serves essential regulatory functions through complex formation with UBE2N and interaction with various E3 ligases and downstream effectors. Understanding UBE2V1’s precise roles in different cell types and disease contexts will be essential for developing targeted therapeutic interventions for neurodegenerative diseases.